Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Tóm tắt
A trade-off exists between affordability of pharmaceutical products today and incentives for firms to provide new and better drugs in the future; an activity that prior studies suggest correlates with profitability, which in turn depends on price regulation. In this paper we re-examined the relationship between price regulation and pharmaceutical research and development (R&D) intensity, and explored the role of profitability and cash flow in mediating this relation using the latest available data from 2000 to 2017 for the 10 most innovative pharmaceutical companies. Following a framework similar to a previous study, we exploited stylized facts about sales volumes in Europe and USA, which give rise to variation in exposure to price regulation. Using ordinary least squares fixed effects models, we assess whether price regulation is related to R&D investment through cash flow effects and profitability. While exposure to price regulation (measured by relative market share in EU/USA) is related negatively to R&D intensity, and this result is driven by price regulation being negatively related to cash flow and profitability, the results were not significant when firm fixed effects were added to the regression models. Modeling firm dynamics showed that cash flow and profitability of European- and US-based firms responded differently to exposure to price regulation. Thus, firm specific effects play an important role in explaining the negative relationship between price regulation and R&D intensity. These results were robust to the inclusion of different time-varying firm level variables. The findings suggest that investment decisions of firms are most likely driven by long-run inter-firm differences, and that firm effects strongly determine firm strategies in terms of R&D investment.
Tài liệu tham khảo
Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets. Pharmacoeconomics. 2011;29(1):17–33.
Kessler DP. The effects of pharmaceutical price controls on the cost and quality of medical care: a review of the empirical literature. US Department of Commerce and International Trade Administration. 2004. https://www.citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.461.4648&rep=rep1&type=pdf. Accessed 20 Jan 2020.
Danzon PM. Regulation of price and reimbursement for pharmaceuticals. In: The Oxford Handbook of the Economics of the Biopharmaceutical Industry; 2012.
Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Kaitelidou D. Pharmaceutical regulation in 15 European countries. Health Syst Transit. 2016;18(5):1–118.
Atella V, Bhattacharya J, Carbonari L. Pharmaceutical price controls and minimum efficacy regulation: evidence from the United States and Italy. Health Serv Res. 2012;47(1 pt 1):293–308.
Sood N, De Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff. 2008;27(Suppl 1):w125–w137137.
Danzon PM, Chao LW. Does regulation drive out competition in pharmaceutical markets? J Law Econ. 2000;43(2):311–58.
Dubois P, De Mouzon O, Scott-Morton F, Seabright P. Market size and pharmaceutical innovation. RAND J Econ. 2015;46(4):844–71.
Abbott TA, Vernon JA. The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions. Manag Decis Econ. 2007;28(4–5):293–306.
Grabowski HG. The determinants of industrial research and development: a study of the chemical, drug, and petroleum industries. J Polit Econ. 1968;76(2):292–306.
Grabowski HG, Mueller DC. Industrial research and development, intangible capital stocks, and firm profit rates. Bell J Econ. 1978;9(2):328–43.
Grabowski HG, Vernon J. The determinants of pharmaceutical research and development expenditures. J Evol Econ. 2000;10(1–2):201–15.
Scherer FM. The link between gross profitability and pharmaceutical R&D spending. Health Aff. 2001;20(5):216–20.
Giaccotto C, Santerre RE, Vernon JA. Drug prices and research and development investment behavior in the pharmaceutical industry. J Law Econ. 2005;48(1):195–21414.
Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 2005;14(1):1–16.
Vernon JA. The relationship between price regulation and pharmaceutical profit margins. Appl Econ Lett. 2003;10(8):467–70.
Golec J, Vernon JA. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms. Pharmacoeconomics. 2010;28(8):615–28.
Golec J, Hegde S, Vernon JA. Pharmaceutical R&D spending and threats of price regulation. J Financ Quant Anal. 2010;45(1):239–64.
Bardey D, Bommier A, Jullien B. Retail price regulation and innovation: reference pricing in the pharmaceutical industry. J Health Econ. 2010;29(2):303–16.
Eger S, Mahlich JC. Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Econ Rev. 2014;4(1):23.
WRDS-Database. Compustat Fundamentals Annual and Quarterly. 2018. https://www.wrdsweb.wharton.upenn.edu/wrds/. Accessed 20 Jan 2020.
FED. Foreign Exchange Rates, Federal Reserve of the United States of America. 2020. https://www.federalreserve.gov/releases/g5a/current/. Accessed 20 Jan 2020.
Cockburn IM, Henderson RM. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. J Health Econ. 2001;20(6):1033–57.
Finkelstein A. Static and dynamic effects of health policy: evidence from the vaccine industry. Q J Econ. 2004;119(2):527–64.
Henderson R, Cockburn I. Measuring competence? Exploring firm effects in pharmaceutical research. Strateg Manag J. 1994;15(S1):63–84.
Bogner WC, Thomas H. Core competence and competitive advantage: a model and illustrative evidence from the pharmaceutical industry. In: Hamel G, Heene A, editors. Competence-based competition. Chichester: John Wiley & Sons; 1994. p. 111–44.
Lippman, SA, Rumelt, RP. Uncertain imitability: an analysis of interfirm differences in efficiency under competition. Bell J Econ. 1982; 418–438.
Mauri AJ, Michaels MP. Firm and industry effects within strategic management: an empirical examination. Strateg Manag J. 1998;19(3):211–9.
Ghemawat P. Commitment: the dynamic of strategy. New York: Free Press; 1991.
Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88–99.
Kyle MK. The role of firm characteristics in pharmaceutical product launches. Rand J Econ. 2007;37(3):602–18.
Wooldridge JM. Introductory econometrics: a modern approach. Oxford: Nelson Education; 2016.